fashion -WSS

fashion

author：knowledge 2025-10-02 13:41:03 - browse：86

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Group behind ProMed defends move to subscription

entertainment

WSS

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Heart disease in astronauts blamed on cosmic radiation

Food as medicine: Medically tailored meals may get standardized

Physicians aren't 'burning out.' They're suffering from moral injury

When waiting feels immoral: Empathy in the emergency department

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

Group behind ProMed defends move to subscription

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Medical leaders decry Supreme Court decision on affirmative action

Physicians aren't 'burning out.' They're suffering from moral injury

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Chris Christie meets with Zelenskyy during Ukraine trip

Cancer drug shortages should be causing more outrage

Primary care physicians play key roles in Alzheimer's management

focus

A controversial new treatment promises to make little people taller

A controversial new treatment promises to make little people taller

Roche subsidiary Foundation Medicine opens new headquarters

Decaf coffee targeted by food safety group under obscure FDA rule

Readout LOUD podcast: mifepristone case, GLP

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

entertainment

explore

hotspot

Wikipedia